The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
Ruxandra Draghia, Nina Hill, Bruce M. Altevogt, Kenneth A. Bradley, Kelly Chibale, Tomáš Cihlář, Barry Clinch, James F. Demarest 等 9 位
Novavax (United States) F. Hoffmann-La Roche AG University of Cape Town Institute of Infectious Disease and Molecular Medicine
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Harbingers of infectious viral pandemics, such as the H1N1 influenza, SARS, Zika, Ebola, MERS, and SARS-CoV-2, caused major outbreaks in the first two decades of the 21st century. Despite warnings, therapeutic tools that could be rapidly and sustainably scaled at a global level when SARS-CoV-2 emerged were lacking. Small-molecule antivirals can play a crucial role in both individual patient care and broader public health strategies for controlling and mitigating the impact of viral diseases. Despite their utility, the lack of R&D investment in this class of intervention has prevented the world from reaping the benefits they can deliver. The INTREPID Alliance 2025 publication of the Antiviral Clinical and Preclinical Development Landscape-4th Edition, revealed significant gaps in the development pipeline. No antivirals are in clinical development for 4 of the 13 viral families designated by the World Health Organization as viral families of pandemic and endemic concern.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Viral Infections and Outbreaks Research
SARS-CoV-2 and COVID-19 Research · Respiratory viral infections research